Heterocycles useful in the treatment of benign prostatic hyperplasia

US6841682B2 · kind B2 · utility

Assignee

• Janssen Pharmaceutica NA · BE

Inventors

• Richard Hutchings · Ann Arbor, US
• Haripada Khatuya · San Diego, US
• Gee-Hong Kuo · Scotch Plains, US
• Xiaobing Li · San Diego, US
• William V. Murray · Montgomery, US
• Catherine P. Prouty · Doylestown, US
• Frank J. Villani · Perkasie, US
• Nelson C. Yim · Ambler, US
• Cynthia Maryanoff · Robinson Township, US

Key dates

• Filing date: Nov 26, 2001
• Grant date: Jan 11, 2005
• Expiry date: Dec 6, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the α-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.